Surgical Resection and Ablative Therapies for Hepatocellular Carcinoma
Ablative Lung Cancer Therapies - cdn.ymaws.com
Transcript of Ablative Lung Cancer Therapies - cdn.ymaws.com
![Page 1: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/1.jpg)
Ablative Lung Cancer Therapies
Jeremiah T. Martin MBBCh FRCSI MSCRDPortsmouth, Ohio
![Page 2: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/2.jpg)
No Disclosures
![Page 3: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/3.jpg)
Introduction
![Page 4: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/4.jpg)
Introduction
![Page 5: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/5.jpg)
Scioto CountyData from ODH OCISS
Incidence* Mortality* Early Stage#
Scioto Ohio US Scioto Ohio US Scioto Ohio USLung 87.9 69.9 55.8 71.6 52.7 44.7 19.0 18.0 19.0
* - Data are number of patients per 100,000 population# - Data are proportion / percentage
1 Source of Ohio data: Ohio Cancer Incidence Surveillance System and the Bureau of Vital Statistics, Ohio Department of Health, 2017. 2 Source of U.S. data: Surveillance, Epidemiology and End Results Program, National Cancer Institute and the National Center for Health Statistics, 2017. 3 Rates are per 100,000 and age-adjusted to the 2000 U.S. standard population. Rates are sex specific for cancers of the breast,
![Page 6: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/6.jpg)
Current Landscape
Kentucky Cancer Registry:2010 – 2012:
Surgical Patients 1
30% Minimally Invasive
2005 – 2014: Intent-to-treat (cI/cII) 2
60% Surgical
25% Radiation / Local Therapy
15% No local therapy
1. Martin, Jeremiah T., et al. "Nodal upstaging during lung cancer resection is associated with surgical approach." The Annals of thoracic surgery 101.1 (2016): 238-245.
2. Martin, Jeremiah T. “Disparities in stage-appropriate therapy for resectable non-small cell lung cancer in kentucky”. In Preparation.
![Page 7: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/7.jpg)
Early Stage Lung Cancer
Early Detection
Early Therapy
![Page 8: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/8.jpg)
Local Therapy
SurgeryOpen
VATS
Robot
AblationThermal
RFA
Laser
Microwave
Cryotherapy
Electroporation
RadiationSAbR / SBRT
Proton
![Page 9: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/9.jpg)
Ablation
![Page 10: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/10.jpg)
Radiofrequency Ablation
• Oscillating voltage: 375 - 500 kHz image-guided electrode
• Frictional heat, impedance is measured
Image: upmc.com
![Page 11: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/11.jpg)
Radiofrequency Ablation
ACSOG Z4033Published 2015
51 patients, cIA NSCLCImage-guided RFA, retreatment of any local recurrence
86.3% at 1 year 69.8% at 2 yearsRecurrence free: 68.9% and 69.8%
Dupuy DE, Fernando HC, Hillman S, Ng T, Tan AD, Sharma A, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121(19):3491-8.
![Page 12: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/12.jpg)
Radiofrequency Ablation
Potential Advantages:
• Well tolerated in frail patients
• Retreatment is possible
• Comparable outcomes to SBRT
Limitations:
• Technical – heat-sink, poor conduction
Angiodynamics StarBurst
![Page 13: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/13.jpg)
Microwave Ablation
• Percutaneous / Bronchoscopic
• Local MW heating - > 60C
• EM energy: 300MHz - 300GHz
Image courtesy NeuWave
![Page 14: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/14.jpg)
Microwave Ablation
Microwave Ablation of Lung Neoplasms2016
Retrospective review: 108 patients
- Primary success in 80%- More likely with tumors < 3cm- 62% of tumors > 3cm- vs 23%-40% in RFA
OS: 78% 1y 54% 2y 39% 3y
Healey TT, March BT, Baird G, Dupuy DE. Microwave Ablation for Lung Neoplasms: A Retrospective Analysis of Long-Term Results. J Vasc Interv Radiol. 2016.
![Page 15: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/15.jpg)
Cryoablation
Cell death < -40ºC
Less discomfort than RF
Five Year Survival after CryoablationPublished 2015
47 cI patients 2006-2011
67% at 5 years
Moore W, Talati R, Bhattacharji P, Bilfinger T. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. 2015;26(3):312-9.
![Page 16: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/16.jpg)
“Contact” ablation
• Percutaneous• More precise
• Invasive
• Pneumothorax
• Bronchoscopic• Less invasive
• Less precise
… is there anything else
on the horizon?
![Page 17: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/17.jpg)
![Page 18: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/18.jpg)
Stereotactic Radiation
• Stereotactic radiation (SBRT)/(SABR)
![Page 19: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/19.jpg)
SBRT
• Radiation: • minimize collateral damage: fractionation
• SBRT:
• Large radiation dose per fraction
• Precisely delivered to target area
• Minimal damage to surrounding tissues
• Disadvantage – no tissue, no lymph nodes
![Page 20: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/20.jpg)
SBRT
• Treatment of choice for early stage, medically inoperable patients. Control of symptomatic metastases.
• RTOG 0236: 59 biopsy proven T1/2N0M0• 3-year primary control rate was 98%
• 3-year disease free survival was 48%• Distant relapse
![Page 21: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/21.jpg)
Particle Therapy
Conventional radiation X-Rays (Photons) - Linear Accelerator
Proton therapyProton beam - cyclotron
Hydrogen
![Page 22: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/22.jpg)
Particle Therapy
Protons carry a charge and have mass
Bragg PeakProtons slow down…
Deliver a burst of energy
![Page 23: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/23.jpg)
Particle Therapy
• Protons carry a charge and have mass
• Bragg Peak• Protons slow down
• Deliver a burst of energy
![Page 24: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/24.jpg)
Proton Therapy
1946 – Proposed as a therapy
1954 – MGH Harvard Cyclotron Laboratory
1990 – First US hospital based center: Loma Linda
Today:27 centers in the USA
14 more in development
http://www.ptcog.ch/index.php/facilities-in-operation
![Page 25: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/25.jpg)
Cost and Infrastructure
![Page 26: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/26.jpg)
Mevion S250
With permission: from MevionMevion S250 Hyperscan
![Page 27: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/27.jpg)
Clinical Trials
Source: clinicaltrials.gov
![Page 28: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/28.jpg)
Stable-mates Trial
A Randomized Phase III Study of SublobarResection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
![Page 29: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/29.jpg)
Stable-mates Trial
84 patients enrolled as of March 2018; Goal 272
![Page 30: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/30.jpg)
Limitations of Ablation
• Tissue• Medical oncology
• Imaging• Microscopic tumor extension
• Lymph-vascular invasion
• Lymph node involvement (N1)
![Page 31: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/31.jpg)
Summary
Ablation and Surgerycomplementary roles
Surgeons must remain engaged
![Page 32: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/32.jpg)
Summary
![Page 33: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/33.jpg)
Ideal Local Therapy
Minimal / No pain
Minimal loss of quality of life
High success rate
Reproducible / Generalizable
Cost effective
![Page 34: Ablative Lung Cancer Therapies - cdn.ymaws.com](https://reader034.fdocuments.in/reader034/viewer/2022050612/627409b6245b552c6e7a2e93/html5/thumbnails/34.jpg)
Ablative Lung Cancer Therapies
Safety Quality Service Relationships Performance
Jeremiah T [email protected]